NO953961L - Antihypertriglyseridemisk sammensetning - Google Patents

Antihypertriglyseridemisk sammensetning

Info

Publication number
NO953961L
NO953961L NO953961A NO953961A NO953961L NO 953961 L NO953961 L NO 953961L NO 953961 A NO953961 A NO 953961A NO 953961 A NO953961 A NO 953961A NO 953961 L NO953961 L NO 953961L
Authority
NO
Norway
Prior art keywords
hypertriglyceride
epidemic
composition
hypertriglyceride epidemic
epidemic composition
Prior art date
Application number
NO953961A
Other languages
English (en)
Other versions
NO308580B1 (no
NO953961D0 (no
Inventor
Yasuo Sugiyama
Hidefumi Yukimasa
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of NO953961D0 publication Critical patent/NO953961D0/no
Publication of NO953961L publication Critical patent/NO953961L/no
Publication of NO308580B1 publication Critical patent/NO308580B1/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/55131,4-Benzodiazepines, e.g. diazepam or clozapine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
NO953961A 1994-10-07 1995-10-05 Anvendelse av kondenserte cykliske forbindelser for fremstilling av en antihypertriglyceridemisk medisin NO308580B1 (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP24413694 1994-10-07

Publications (3)

Publication Number Publication Date
NO953961D0 NO953961D0 (no) 1995-10-05
NO953961L true NO953961L (no) 1996-04-09
NO308580B1 NO308580B1 (no) 2000-10-02

Family

ID=17114301

Family Applications (1)

Application Number Title Priority Date Filing Date
NO953961A NO308580B1 (no) 1994-10-07 1995-10-05 Anvendelse av kondenserte cykliske forbindelser for fremstilling av en antihypertriglyceridemisk medisin

Country Status (11)

Country Link
EP (1) EP0705607A2 (no)
KR (1) KR960013370A (no)
CN (1) CN1128657A (no)
AU (1) AU703422B2 (no)
CA (1) CA2160092A1 (no)
FI (1) FI954773A7 (no)
HU (1) HUT73422A (no)
NO (1) NO308580B1 (no)
NZ (1) NZ280165A (no)
RU (1) RU2166320C2 (no)
TW (1) TW401301B (no)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69637603D1 (de) * 1995-09-13 2008-08-28 Takeda Pharmaceutical 5-(2,3-Dialkoxyphenyl)-4,1-benzoxazepin-2-one als anti-hyperlipidämische Mittel
AU6944296A (en) * 1995-09-13 1997-04-01 Takeda Chemical Industries Ltd. Benzoxazepine compounds, their production and use as lipid lowering agents
EP0843559A2 (en) * 1996-06-11 1998-05-27 Zonagen, Inc. Chitosan drug delivery system
DE69832376T2 (de) 1997-04-21 2006-08-03 Takeda Pharmaceutical Co. Ltd. 4,1-benzoxazepine, ihre analoga, und ihre verwendung als somatostatin-agonisten
JP4204657B2 (ja) * 1997-12-05 2009-01-07 有限会社ケムフィズ 糖尿病の予防・治療剤
CA2383983C (en) 1998-03-31 2009-09-29 The Institutes For Pharmaceutical Discovery, Llc Substituted indolealkanoic acids
US6207664B1 (en) 1998-11-25 2001-03-27 Pfizer Inc. Squalene synthetase inhibitor agents
TNSN99224A1 (fr) 1998-12-01 2005-11-10 Inst For Pharm Discovery Inc Methodes de reduction des niveaux de glucose et triglyceride en serum et pour suppression de l'antigenese utilisant les acides la indolealkanoique
EP1183242A2 (en) 1999-05-26 2002-03-06 Du Pont Pharmaceuticals Company 1,4-benzodiazepin-2-ones useful as hiv reverse transcriptase inhibitors
MXPA02001340A (es) * 1999-08-05 2004-07-16 Prescient Neuropharma Inc Compuestos novedosos 1,4-benzodiazepina y derivados de los mismos.
CA2428669A1 (en) * 2000-11-09 2002-05-16 Takeda Chemical Industries, Ltd. High-density lipoprotein-cholesterol level elevating agent
US7067148B2 (en) 2001-02-15 2006-06-27 King Pharmaceutical Research & Development, Inc. Stabilized pharmaceutical and thyroid hormone compositions and method of preparation
US20030027786A1 (en) * 2001-06-06 2003-02-06 Karsten Maeder Lipase inhibiting composition
WO2003002147A1 (en) * 2001-06-28 2003-01-09 Takeda Chemical Industries, Ltd. Preventives/remedies for organ functional disorders and organ dysfunction
US7101569B2 (en) 2001-08-14 2006-09-05 Franz G Andrew Methods of administering levothyroxine pharmaceutical compositions
US7625887B2 (en) 2003-01-28 2009-12-01 Takeda Pharmaceutical Company Limited Receptor agonists
CN1882327A (zh) 2003-11-19 2006-12-20 症变治疗公司 含磷的新的拟甲状腺素药
WO2006016681A2 (en) * 2004-08-09 2006-02-16 Takeda Pharmaceutical Company Limited Crp lowering agent
WO2007048027A2 (en) 2005-10-21 2007-04-26 Novartis Ag Combination of a renin-inhibitor and an anti-dyslipidemic agent and/or an antiobesity agent
US7790745B2 (en) 2005-10-21 2010-09-07 Bristol-Myers Squibb Company Tetrahydroisoquinoline LXR Modulators
US9096546B2 (en) 2007-05-10 2015-08-04 Albany Molecular Research, Inc. Aryl- and heteroaryl-substituted tetrahydrobenzo-1,4-diazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
US20120046364A1 (en) 2009-02-10 2012-02-23 Metabasis Therapeutics, Inc. Novel Sulfonic Acid-Containing Thyromimetics, and Methods for Their Use
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
KR102698413B1 (ko) 2020-05-05 2024-08-26 뉴베일런트, 아이엔씨. 헤테로방향족 거대환식 에터 화학치료제
IL297832A (en) 2020-05-05 2023-01-01 Nuvalent Inc Macrocyclic heteroaromatic chemotherapeutic agents
IL311444A (en) 2021-10-01 2024-05-01 Nuvalent Inc Solid forms, pharmaceutical compositions and preparation of heteroaromatic macrocyclic ether compounds

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5180717A (en) * 1988-08-16 1993-01-19 The Upjohn Company Bivalent ligands effective for blocking ACAT enzyme for lowering plasma triglycerides and for elevating HDL cholesterol
FR2659332B1 (fr) * 1990-03-08 1994-04-29 Adit Et Cie Nouvelles pyrrolo [1,2-a] thieno [3,2-f] diazepines [1,4], leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
DE69332792T2 (de) * 1992-04-20 2004-01-15 Takeda Chemical Industries Ltd 4,1-Benzoxazepinderivate als Squalen-Synthetase Inhibitoren und ihre Verwendung zur Behandlung von Hypercholesterämie und als Fungizide
TW225992B (no) * 1992-07-17 1994-07-01 Senju Pharma Co
AU678503B2 (en) * 1993-09-24 1997-05-29 Takeda Chemical Industries Ltd. Condensed heterocyclic compounds and their use as squalene synthetase inhibitors
AU1589895A (en) * 1994-02-09 1995-08-29 Takeda Chemical Industries Ltd. Optically active 4,1-benzoxazepine derivatives useful as squalene synthase inhibitors

Also Published As

Publication number Publication date
RU2166320C2 (ru) 2001-05-10
NO308580B1 (no) 2000-10-02
NO953961D0 (no) 1995-10-05
CN1128657A (zh) 1996-08-14
KR960013370A (ko) 1996-05-22
AU3308195A (en) 1996-04-18
FI954773A0 (fi) 1995-10-06
HU9502918D0 (en) 1995-11-28
TW401301B (en) 2000-08-11
EP0705607A2 (en) 1996-04-10
EP0705607A3 (no) 1996-05-08
CA2160092A1 (en) 1996-04-08
FI954773A7 (fi) 1996-04-08
NZ280165A (en) 1997-07-27
HUT73422A (en) 1996-07-29
AU703422B2 (en) 1999-03-25

Similar Documents

Publication Publication Date Title
DE69526966D1 (de) Hautkräftigende kometische zusammensetzung
NO953961L (no) Antihypertriglyseridemisk sammensetning
FI974241L (fi) BPM-15 -koostumukset
DE69423670D1 (de) Siloxy-aluminoxan-Zusammensetzungen
BR9508844A (pt) Composição oral
DE69520871D1 (de) Glaszusammensetzungen
ID16251A (id) Komposisi-komposisi pembasmi kuman
BR9508318A (pt) Composição impadora concentrada
BR9506536A (pt) Composição oral
DE69530614D1 (de) Iontophorese pflaster
ATE209959T1 (de) Mikroverkapselte zusammensetzungen
BR9606809A (pt) Composição inseticidamente ativa
BR9607058A (pt) Composição
DE69733072D1 (de) Farbschonende zusammensetzungen
BR9510467A (pt) Composições orais
DE69512397D1 (de) Wärmehärtende zusammensetzung
DE69617029D1 (de) Organoton-zusammensetzungen
NO981568D0 (no) Randtennings-tennsatssammensetninger
DE69719442D1 (de) Frisierschaum-Zusammensetzungen
PT728814E (pt) Composicao betuminosa
BR9510307A (pt) Composições orais
DE69503738D1 (de) Fotopolymerisierbare Zusammensetzung
BR9609903A (pt) ComposiçÃo inseticidamente ativa
ITMI940362A0 (it) Composizione antitosse
DE69603228D1 (de) Aluminoxanate-Zusammensetzungen

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees

Free format text: LAPSED IN APRIL 2003